标题：关于湖北华强科技股份有限公司有关事项的监管工作函 证券代码：688151 证券简称：华强科技 监管类型：监管工作函 涉及对象：上市公司 处分日期：2024-05-13 处理事由：关于湖北华强科技股份有限公司有关事项的监管工作函 ...

2023 年年度股东大会会议资料 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2023 年年度股东大会 会议资料 二〇二四年五月 | 湖北华强科技股份有限公司 | | 2023 年年度股东大会会议须知 | 1 | | --- | --- | --- | --- | | 湖北华强科技股份有限公司 | | 2023 年年度股东大会会议议程 | 4 | | 报告一： | | | 6 | | 独立董事 | 2023 | 年度述职报告（王广昌） | 6 | | 独立董事 | 2023 | 年度述职报告（刘洪川） | 15 | | 独立董事 | 2023 | 年度述职报告（刘景伟） | 24 | | 议案一 | ：2023 | 年度董事会工作报告 | 33 | | 议案二 | ：2023 | 年度监事会工作报告 | 50 | | 议案三 | ：2023 | 年年度报告全文及其摘要 | 55 | | 议案四 | ：2023 | 年度财务决算报告 | 56 | | 议案五 | ：2024 | 年度财务预算方案 | 63 | | 议案六 | ：2023 | 年度利润分配方案 | 65 | | 议案七 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照中国证监会《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、上海证券交易所颁布的《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》及相关格式指引的要求，现将湖北华强科技股份 有限公司（以下简称"公司"或"华强科技"）2023 年度募集资金存放与实际使用情 况报告如下： 证券代码：688151 证券简称：华强科技 公告编号：2024-017 湖北华强科技股份有限公司 关于2023年度募集资金存放与实际使用情 况的专项报告 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意湖北华强科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2021]3368 号）同意注册，公司向社会公众公 开发行人民币普通股（A 股）8,620.62 万股，每股面值人民币 1 元，每股发行价 为人民币 35.09 元，募集资金总额为人民币 3,024,975,558.00 元，扣除发行费用 （不含增值税）人民 ...

Financial Performance - The total distributable profit as of December 31, 2023, is RMB 235,276,213.60, with the parent company's distributable profit at RMB 213,599,678.39[5]. - The proposed cash dividend is RMB 0.083 per share (before tax), totaling RMB 2,859,350.00 based on a total share capital of 344,500,000 shares[5]. - The net profit attributable to shareholders for the year is RMB 7,925,121.12, with a cash dividend payout ratio of 36.08%[5]. - The company's operating revenue for 2023 was CNY 572.75 million, a decrease of 2.21% compared to CNY 585.68 million in 2022[21]. - The net profit attributable to shareholders for 2023 was a loss of CNY 76.03 million, representing a decline of 88.36% from a profit of CNY 68.07 million in 2022[22]. - The basic earnings per share for 2023 was CNY 0.02, down 90.00% from CNY 0.20 in 2022[23]. - The company's cash flow from operating activities showed a net outflow of CNY 66.88 million, which is an improvement of 63.11% compared to the previous year[25]. - The total assets of the company at the end of 2023 were CNY 5.05 billion, a decrease of 2.13% from CNY 5.16 billion at the end of 2022[22]. - The weighted average return on equity for 2023 was 0.19%, a decrease of 1.41 percentage points from 1.60% in 2022[23]. - The company reported a total of CNY 83.95 million in non-recurring gains for 2023, compared to CNY 80.99 million in 2022[30]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Management Discussion and Analysis" section[4]. - The report includes a forward-looking statement risk disclaimer, indicating that future plans and strategies do not constitute a commitment to investors[7]. - The company is at risk of potential losses if adverse factors affecting its performance continue to worsen, particularly in the pharmaceutical packaging sector[75]. - The company is exposed to financial risks, including a significant reliance on foreign suppliers for raw materials, which may impact production and cost control[79]. - The company faces risks related to large accounts receivable, which amounted to CNY 634.24 million, accounting for 16.66% of current assets[81]. - The company is exposed to risks from military procurement fluctuations and pricing delays, which could impact revenue and performance[82]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[8]. - The board of directors has approved the profit distribution plan, which is subject to shareholder meeting approval[5]. - The company has established a comprehensive internal control system to enhance decision-making and operational efficiency, with a 100% control rate on 39 management system changes during the reporting period[196]. - The company emphasizes ESG practices, integrating environmental and social responsibility into daily operations, and adheres to carbon neutrality goals[198]. - The governance mechanism ensures professional and efficient internal discussions and decision-making processes[200]. - The company focuses on protecting investor rights and interests through transparent governance practices[200]. Research and Development - Research and development expenses accounted for 9.03% of operating revenue, down from 11.34% in the previous year[23]. - The company invested 9.03% of its revenue in R&D, applying for 47 patents in total, including 25 invention patents[37]. - The company has achieved significant technological advancement in the production of pharmaceutical rubber stoppers, establishing a comprehensive formula system and mature production processes, positioning itself at the forefront of the industry both domestically and internationally[52]. - The company is committed to increasing R&D investment to enhance its independent innovation capabilities and aims to establish a robust technology system for key innovations[130]. - The company has established long-term partnerships with various research institutions and universities to enhance its R&D capabilities[72]. Market and Product Development - The company is actively expanding into the pharmaceutical packaging and medical device markets, including non-PVC multi-layer co-extruded films and medical protective clothing[70]. - The company is exploring new directions in mask production, particularly with the development of nano masks, which are expected to become a new trend in medical protective equipment[57]. - The company plans to complete the development of the "Filtering Absorber XX" project by 2024, with a total investment of RMB 1,369.61 million, and has achieved prototype testing[64]. - The company is focused on expanding its market presence in military products while maintaining quality and timely delivery of military supplies[134]. - The company anticipates intensified competition in the military supplies sector as market access barriers are lowered, allowing more enterprises to enter the industry[125]. Operational Efficiency - The company has implemented smart manufacturing in its production processes, achieving a 51% increase in production efficiency and a 20% reduction in operating costs[70]. - The company has established a production capacity for the "Insulin Pen Injector Components," with a total investment of RMB 514.97 million, and is entering the review process in 2024[64]. - The company has completed 59 training projects in 2023, covering various employee groups to improve knowledge structure and business quality[184]. - The company maintains a direct sales model for all products, with no distribution model in place, ensuring control over sales processes[95]. - The company has implemented a performance evaluation mechanism for senior management, linking compensation to market standards and performance contributions[195]. Shareholder Engagement - The company held 4 shareholder meetings during the reporting period, reviewing 17 proposals[140]. - The company actively engaged with investors through various communication channels, enhancing transparency and investor relations[142]. - The company has not issued any new shares or made any changes to the existing shareholding structure during the reporting period[148]. - The company reported a total revenue of 64.48 million CNY for the year, with no changes in shareholding for key executives[147]. - The company has established a remuneration decision-making process that involves shareholder meetings and board reviews[161].

湖北华强科技股份有限公司 2024 年度"提质增效重回报"行动方案 为深入贯彻党中央、国务院决策部署,认真落实中央经济工作会议、中央金 融工作会议精神,根据国务院国资委《关于印发〈提高央企控股上市公司质量工 作方案〉的通知》等相关文件要求,湖北华强科技股份有限公司(以下简称"公 司")积极响应并践行以投资者为本的发展理念,2024年将继续履行强军首责、 聚焦主责主业,强化科技创新驱动,持续提高国防装备质量,提升企业价值,积 极回报全体股东,结合公司实际情况,制定本实施方案。 一、认清形势、坚定信心,坚决贯彻落实中央经济工作会议精神 中央经济工作会议对当前和今后一个时期形势做了深刻分析,对下一步发展 提出了明确要求。会议强调,做好 2024年经济工作,要以习近平新时代中国特 色社会主义思想为指导,全面贯彻落实党的二十大和二十届二中全会精神,坚持 稳中求进工作总基调,完整、准确、全面贯彻新发展理念,加快构建新发展格局, 着力推动高质量发展,全面深化改革开放,推动高水平科技自立自强。会议要求, 2024 年要坚持稳中求进、以进促稳、先立后破,多出有利于稳预期、稳增长、 稳就业的政策,在转方式、调结构、提质量、增效益 ...

Financial Corrections - The company corrected its financial reports for 2021, 2022, and the first half of 2023 due to insufficient revenue recognition, inadequate inventory impairment provisions, and cross-period cost issues, affecting revenue, costs, and profits without changing the overall profit or loss nature[2][3][13]. - For the 2021 annual report, the company reduced accounts receivable and revenue by CNY 526,460.17, adjusted net profit down by CNY 1,031,377.67, and decreased retained earnings by CNY 928,239.90[6][13]. - In the 2022 annual report, the company adjusted revenue down by CNY 23,727,654.87 and reduced net profit by CNY 4,361,070.62, while also increasing inventory impairment losses by CNY 12,492,262.60[9][10][13]. - The adjustments resulted in a net profit impact of -CNY 103.14 million for 2021, +CNY 103.14 million for the first half of 2022, -CNY 436.11 million for 2022, and -CNY 64.84 million for the first half of 2023[13]. Financial Metrics Adjustments - The company's accounts receivable decreased by CNY 500,137.16 to CNY 605,029,206.66 as a result of the corrections[15]. - Inventory increased by CNY 526,460.17 to CNY 181,744,196.07 following the adjustments[15]. - The company’s deferred tax assets were adjusted by CNY 16,086.12, resulting in a new total of CNY 26,508,653.00[15]. - The adjustments to accounts payable increased by CNY 1,073,786.80, bringing the total to CNY 329,525,531.34[15]. - The company's total revenue for the fiscal year 2021 was adjusted to approximately CNY 1,274.72 million, reflecting a decrease of 0.04% due to corrections[16]. - For the first half of 2022, the adjusted revenue was CNY 343.65 million, an increase of 0.15% compared to the previous figure[18]. - The net profit for the fiscal year 2022 was revised to CNY 68.07 million, showing a decrease of 6.02% after adjustments[21]. - As of June 30, 2023, the company's total assets were reported at approximately CNY 5,080.50 million, reflecting a slight increase of 0.03%[24]. - The adjusted net profit for the first half of 2023 was CNY 28.32 million, a decrease of 2.24% compared to the previous figure[24]. - The company's total liabilities as of December 31, 2022, were adjusted to CNY 376.72 million, reflecting a minor increase of 0.18%[21]. - The adjusted gross profit margin for the fiscal year 2022 was reported at 26.0%, indicating a decrease from the previous year[21]. - The company experienced a significant increase in asset impairment losses, with a correction showing a decrease of 454.65% for the fiscal year 2022[21]. Project Investments - The cumulative investment in the "New Type Nuclear Biological Emergency Rescue Protective Equipment Industrialization Production Base" project was adjusted to ¥21,934,822.38, with a progress rate of 2.84%[26]. - The cumulative investment in the "New Type Nuclear Biological Protective Basic Material R&D Platform Construction Project" was adjusted to ¥1,341,866.00, with a progress rate of 0.38%[26]. Management and Compensation - The total remuneration for key management personnel was corrected to ¥697.56 million for the current period, up from ¥603.19 million[28]. - The total remuneration for non-independent directors and supervisors was disclosed as ¥943,700 in the 2022 annual report[28]. - The company reported additional related party transactions totaling ¥1,566,379.33 for employee compensation with China Weapon Equipment Group Co., Ltd.[29]. Compliance and Future Measures - The audit committee confirmed that the corrections made to the financial reports comply with relevant accounting standards and accurately reflect the company's financial status[31]. - The supervisory board agreed that the corrections to the financial data do not harm the interests of the company and its shareholders[32]. - The accounting firm confirmed that the company's handling of the accounting errors aligns with the applicable accounting standards[33]. - The company plans to enhance supervision and training on financial accounting practices to prevent future issues[34]. - The company expressed apologies for any inconvenience caused to investors due to the financial reporting errors[34].

2023年半年度报告 公司代码：688151 公司简称：华强科技 湖北华强科技股份有限公司 2023 年半年度报告 ...

证券代码：688151 证券简称：华强科技 公告编号：2024-014 湖北华强科技股份有限公司 第二届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 湖北华强科技股份有限公司（以下简称"公司"）第二届监事会第三次会议 （以下简称"本次会议"）于 2024 年 4 月 25 日在公司会议室以现场方式召开， 本次会议通知已于 2024 年 4 月 15 日以邮件方式送达公司全体监事。本次会议由 监事会主席刘跃东先生主持，会议应出席监事 3 人，实际出席监事 3 人。本次会 议的召集、召开符合《中华人民共和国公司法》等法律法规和《湖北华强科技股 份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： （一）审议通过《2023 年度监事会工作报告》 监事会认为：公司《2023 年度监事会工作报告》真实、准确、完整地体现了 公司监事会 2023 年度工作情况。公司监事会在 2023 年度认真遵守《公司法》、 《公司章程》等法 ...

湖 北 华 强 科 技 股 份 有 限 公 司 内 部 控 制 审 计 报 告 天 职 业 字 [2024]22695 号 目 录 内 部控制审计报告一 -1 " 报告 内部控制审计报告 天职业字[2024]22695 号 湖北华强科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了湖 北华强科技股份有限公司(以下简称"华强科技"或"公司")2023年12月31日的财务报告 内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是华强科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 天职业字[2024]22695 号 [此页无正文] 中国注册会计师 (项目合伙人): 010150 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变 ...